NT-201
- Generic Name
- NT-201
A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Merz North America, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT05784363
- Locations
- ๐บ๐ธ
Merz Investigation Site #0010473, Los Angeles, California, United States
๐บ๐ธMerz Investigation Site #001097, Nashville, Tennessee, United States
๐บ๐ธMerz Investigation Site #0010101, Coral Gables, Florida, United States
A Study of NT 201 Doses in the Treatment of Platysma Prominence
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Merz Aesthetics GmbH
- Target Recruit Count
- 73
- Registration Number
- NCT05773053
- Locations
- ๐บ๐ธ
Merz Investigation Site #0010170, Washington, District of Columbia, United States
๐บ๐ธMerz Investigation Site #0010470, Coral Gables, Florida, United States
๐บ๐ธMerz Investigation Site #0010405, New York, New York, United States
A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Merz Pharmaceuticals GmbH
- Target Recruit Count
- 78
- Registration Number
- NCT04766723
- Locations
- ๐บ๐ธ
Mount Sinai Medical Center, Merz Investigational Site #0010191, New York, New York, United States
๐บ๐ธMedstar Georgetown Neurology, Merz Investigational Site #0010231, McLean, Virginia, United States
๐จ๐ฆLondon Health Sciences Centre, Merz Investigational Site #0010087, London, Ontario, Canada
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
- Conditions
- Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Merz North America, Inc.
- Target Recruit Count
- 368
- Registration Number
- NCT04622254
- Locations
- ๐ฉ๐ช
Merz Investigational Site, Wuppertal, Germany
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
- Conditions
- Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Merz North America, Inc.
- Target Recruit Count
- 362
- Registration Number
- NCT04594213
- Locations
- ๐บ๐ธ
Merz Investigational Site, Nashville, Tennessee, United States
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
- Conditions
- Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merz Pharmaceuticals GmbH
- Target Recruit Count
- 603
- Registration Number
- NCT03992404
- Locations
- ๐ง๐ช
CHU Brugmann Neurology; Merz investigational site #0320015, Brussel, Belgium
๐บ๐ฆLviv regional clinical hospital; Merz investigational site # 3800020, Lviv, Ukraine
๐บ๐ธPhysical Medicine and Rehabilitation at University of Alabama at Birmingham; Merz investigational site #0010479, Birmingham, Alabama, United States
Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Merz Aesthetics GmbH
- Target Recruit Count
- 241
- Registration Number
- NCT03806933
- Locations
- ๐บ๐ธ
Medical Associates Inc., Merz Investigational Site #0010435, Newport Beach, California, United States
๐ฉ๐ชSkin & Laser Center, Merz Investigational Site #0490362, Potsdam, Germany
๐บ๐ธClinical Testing of Beverly Hills, Merz Investigational Site #0010395, Encino, California, United States
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
- Conditions
- Chronic Troublesome SialorrheaStrokeTraumatic Brain InjuryIntellectual DisabilityCerebral Palsy
- Interventions
- Drug: NT 201 Placebo
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Merz Pharmaceuticals GmbH
- Target Recruit Count
- 256
- Registration Number
- NCT02270736
- Locations
- ๐ฌ๐ช
Merz Investigational Site #9950001, Tbilisi, Georgia
๐บ๐ฆMerz Investigational Site #3800001, Dnipropetrovsk, Ukraine
๐บ๐ฆMerz Investigational site #3800003, Odesa, Ukraine
Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines
- Conditions
- Healthy
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- Merz Pharmaceuticals GmbH
- Target Recruit Count
- 108
- Registration Number
- NCT00694148
- Locations
- ๐ฉ๐ช
Dr. Matthias Imhof, Medico Palais Bad Soden, Bad Soden, Hessen, Germany
Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Merz Pharmaceuticals GmbH
- Target Recruit Count
- 82
- Registration Number
- NCT00541905
- Locations
- ๐ฉ๐ช
Medizinische Hochschule Hannover (LKP), Hannover, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.